Comparative Pharmacology
Head-to-head clinical analysis: AUSTEDO versus XENAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUSTEDO versus XENAZINE.
AUSTEDO vs XENAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Deuterated tetrabenazine; inhibits vesicular monoamine transporter 2 (VMAT2), reducing dopamine uptake into synaptic vesicles and leading to decreased presynaptic dopamine release, similar to tetrabenazine but with altered pharmacokinetics due to deuterium substitution.
Deutetrabenazine selectively and reversibly inhibits vesicular monoamine transporter 2 (VMAT2), thereby reducing dopamine and monoamine storage and release in presynaptic neurons.
Initial 6 mg orally once daily; titrate by 6 mg increments at weekly intervals to a maximum of 48 mg/day. For tolerability, may divide into twice daily dosing (e.g., 12 mg twice daily).
12.5 mg orally twice daily initially; titrate slowly by 12.5 mg every 3-5 days up to 50 mg twice daily (total daily dose 100 mg). Maximum recommended total daily dose: 100 mg.
None Documented
None Documented
5-9 hours (parent); 7-10 hours (active metabolite). Steady state within 2-3 days.
7-16 hours (mean 9-12 hours); requires twice-daily dosing for steady-state control of chorea.
Urine (75-85% as metabolites, <5% unchanged); feces (10-15%)
Primarily renal (75-85% as metabolites, <2% unchanged); minimal biliary/fecal elimination.
Category C
Category C
VMAT2 Inhibitor
VMAT2 Inhibitor